King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Syed Osman Ali Ahmed
Dr. Syed Osman Ali Ahmed is a Consultant in Adult Haematology, Hematopoietic Stem Cell Transplantation, and Adult CAR-T Cell Lead — a senior acute leukemia specialist in Riyadh, Saudi Arabia. He is internationally recognised for his contributions to AML research and cellular therapy.
- Consultant Adult Hematology / HSCT and Adult CAR-T Cell Lead at a regional centre of excellence
- BSc (Hons), MBBS, MRCP, FRCPath
- 64+ indexed publications and 996 citations on ResearchGate
- Primary investigator — Saudi Acute Myeloid Leukaemia (AML) Genome Study (Blood 2024)
- Editor of Imperial College London alumni research output in hematology
Qualifications & Credentials
Medical Degrees
- BSc (Hons) — Information not publicly available.
- MBBS — Imperial College London, UK
- MRCP — Royal College of Physicians, UK
- FRCPath — Royal College of Pathologists, UK (Haematology)
Fellowships & Special Training
- Adult Haematology / HSCT — King Faisal Specialist Hospital & Research Centre, Riyadh
Certifications & Accreditations
- Member of the Royal College of Physicians (MRCP), UK
- Fellow of the Royal College of Pathologists (FRCPath), UK
- Saudi Commission for Health Specialties (SCFHS) registration
Areas of Expertise
Major Conditions Treated
- Acute Myeloid Leukemia (AML)
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Myeloid Leukemia (CML)
- Myelodysplastic Syndromes (MDS)
- Core-Binding Factor Leukemia (t(8;21); RUNX1-RUNX1T1)
- Fanconi Anemia (adult)
- Aplastic Anemia
- Dyskeratosis Congenita and Inherited Bone Marrow Failure
Sub-specialties
- Adult CAR-T Cell Therapy: Adult CAR-T Cell Lead at a regional centre of excellence — offering point-of-care in-house manufactured CAR-T, a first in Saudi Arabia.
- Hematopoietic Stem Cell Transplantation: Expert in matched sibling, unrelated, and haploidentical transplants with post-transplant cyclophosphamide (PTCy) protocols.
- Acute Leukemia Genomics & Precision Medicine: Lead investigator on the Saudi AML Genome Study, driving precision medicine approaches — key to best AML treatment in Saudi Arabia.
Advanced Procedures & Treatments
- Allogeneic Hematopoietic Stem Cell Transplantation
- Autologous Stem Cell Transplantation
- CD19 CAR-T Cell Therapy (in-house point-of-care manufactured)
- Haploidentical HSCT with Post-Transplant Cyclophosphamide
- AML Induction (7+3) and Consolidation Chemotherapy
- Venetoclax-Based Regimens for AML
- Inotuzumab Ozogamicin for Relapsed ALL
- Sorafenib Maintenance Post-Transplant for FLT3-Mutated AML
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia — Consultant, Adult Haematology / HSCT; Adult CAR-T Cell Lead (Current)
Past Affiliations
- Imperial College London, UK — Medical training
- Information not publicly available.
Academic & Research Roles
- Adjunct Faculty — Alfaisal University, Riyadh
- International collaborator — Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT)
Key Achievements
- 64+ indexed publications and 996+ citations
- Principal investigator on the Saudi AML Genome Study (Blood 2024)
- Lead clinician for Saudi Arabia's first large-scale point-of-care in-house CAR-T programme
- Contributing author on WHO Eastern Mediterranean HSCT strategic priorities position paper
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- Royal College of Physicians, UK (MRCP)
- Royal College of Pathologists, UK (FRCPath)
- Eastern Mediterranean Blood and Marrow Transplantation Group (EMBMT)
- American Society of Hematology (ASH)
Research & Publications
Published Papers (Selected)
- Al-Hashmi S, Almohareb F, Ahmed SOA et al. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1. Blood Adv. 2020;4(1):229-238 (PMC6960481).
- Alfaham MS, Ahmed SO, Seymen N et al. Saudi Acute Myeloid Leukaemia (AML) Genome Reveals Significant Differences from That in the Western Population. Blood. 2024;144(Suppl 1):4231. DOI: 10.1182/blood-2024-205025
- Warda W, El Fakih R, Alrasheed N et al. (incl. Ahmed SO). Large Scale In-House Point-of-Care Manufacturing of Clinical Grade Autologous Anti-CD19 CAR T Cells in Saudi Arabia. medRxiv. 2024.
- Ahmed SO, El Fakih R, Elhaddad A et al. Strategic priorities for hematopoietic stem cell transplantation in the Eastern Mediterranean region. 2022.
Ongoing Research & Clinical Interests
- Acute myeloid leukemia genomics (Saudi population)
- Adult CAR-T cell therapy (in-house manufacturing)
- Core-binding factor leukemia biology
- Haploidentical stem cell transplantation
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Adult Hematology Consultation | SAR 500 – SAR 1,500 | $135 – $400 |
| AML Induction Chemotherapy (7+3) | SAR 80,000 – SAR 200,000 | $21,300 – $53,000 |
| Allogeneic Stem Cell Transplantation | SAR 300,000 – SAR 600,000 | $80,000 – $160,000 |
| Haploidentical HSCT with PTCy | SAR 400,000 – SAR 700,000 | $106,000 – $186,000 |
| In-House CD19 CAR-T Cell Therapy | SAR 500,000 – SAR 1,500,000 | $133,000 – $400,000 |
Frequently Asked Questions
1. What advanced technologies does Dr. Syed Osman Ali Ahmed use as a Hematologist?
Dr. Syed Osman Ali Ahmed uses cutting-edge acute leukemia treatments including in-house point-of-care manufactured CD19 CAR-T cells, haploidentical transplant with post-transplant cyclophosphamide, FLT3 inhibitor maintenance, venetoclax-based regimens, and AML genome-guided precision medicine. International acute leukemia consultations can be arranged via Cancer Rounds.
2. What conditions does Dr. Syed Osman Ali Ahmed specialize in treating?
Dr. Syed Osman Ali Ahmed specialises in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia, myelodysplastic syndromes, inherited bone marrow failure syndromes, and stem cell transplantation. He is a senior acute leukemia specialist in Riyadh regularly sought by international patients with complex hematological malignancies.
3. How do I book an appointment with Dr. Syed Osman Ali Ahmed?
Appointments with Dr. Syed Osman Ali Ahmed can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Syed Osman Ali Ahmed?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Syed Osman Ali Ahmed, including Saudi Arabia medical visa invitation letters, airport transfers, and local accommodation coordination in Riyadh.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation (Arabic, English, and more), financial counselling, and pre-travel virtual consultations to review medical records before arrival in Riyadh.
6. Does Dr. Syed Osman Ali Ahmed offer second opinions as a Hematologist?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with Dr. Syed Osman Ali Ahmed, an expert Hematologist in Riyadh, Saudi Arabia.
